The House Energy and Commerce Committee yesterday released a report on the 340B Drug Pricing Program. “The 340B program is an important program that enjoys strong bipartisan support in Congress,” the report says. “The program helps reduce the prices of covered drugs for certain participating entities who, in turn, provide care for patients.” The report, which comes after two years of the committee examining the operation and oversight of the 340B program, includes a number of findings about the program, as well as 12 recommendations.

Related News Articles

Perspective
Last week, I shared a few areas where we can advance health in America this year, even in a divided Congress.
Headline
Continued rising drug prices, as well as shortages for many critical medications, are disrupting patient care and forcing hospitals to delay infrastructure and…
Perspective
We’re 11 days into 2019 … we’ve returned to a divided government …and the partial government shutdown continues.
Insights and Analysis
Also in this weekly roundup of health news: AHA president and CEO Rick Pollack speaks to HealthLeaders about the association’s year ahead; digital health…
Headline
As Congress prioritizes action to lower drug prices, the Campaign for Sustainable Rx Pricing yesterday announced a website to help lawmakers and their staff…
Headline
AHA commends the Centers for Medicare…